Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).-MedSci.cn

Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).

Lyman, JP; Cabanski, CR; Maddock, S; Wolff, RA; Wainberg, ZA; Ko, AH; Rahma, OE; Fisher, GA; Gabriel, PE; Doucette, A; Zheng-Lin, BB; Maloy, MA; Dugan, U; Fairchild, JP; Spasic, M; O'Donnell-Tormey, J; Vonderheide, RH; O'Hara, MH; O'Reilly, EM

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (): 757

科室
- - 订阅+
  - 更多科室
工具
服务